| Name | Title | Contact Details |
|---|
Provista Life Sciences is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Brammer Bio is focused on providing clinical and commercial supply of autologous and allogeneic cell therapies, and viral vector products for in vivo and ex vivo therapeutic applications. Along with process and analytical development and regulatory support we enable large pharma and biotech clients to accelerate the delivery of novel medicines and improve patient health. Brammer Bio occupies 45,000 ft2 of process development and phase I/II clinical manufacturing space in Alachua, FL, and is developing a 50,000 ft2 facility in Lexington, MA, with plans to build-out large-scale, phase III/commercial ready viral vector manufacturing suites, segregated cell and gene therapy suites, and QC and analytical laboratories for clinical and commercial launch services.
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than 1,000 employees are led by distinguished executives with proven records of success. We are proud to have been recognized by Forbes as one of the World`s Most Innovative Companies for each of the past three years.
San Miguel Technology Llc is a Landenberg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. We are employing our massively parallel, multiplexed, and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease.